CD44 family and gynaecological cancer

被引:0
|
作者
Makrydimas, G
Zagorianakou, N
Zagorianakou, P
Agnantis, NJ [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Pathol, GR-45110 Ioannina, Greece
[2] Univ Ioannina, Sch Med, Dept Obstet & Gynecol, GR-45110 Ioannina, Greece
来源
IN VIVO | 2003年 / 17卷 / 06期
关键词
CD44; gynaecological cancer;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
CD44 refers to a multifunctional family of type I transmembrane proteins. The CD44 gene contains at least 21 exons, 11 of which can be variably spliced and produce a variety of heavily glycosylated cell surface proteins, known as CD44 variant isoforms. These proteins have been implicated in many biological processes, such as cell adhesion, cell substrate, cell to cell interactions, including lymphocyte homing haemopoiesis, cell migration and metastasis. These abilities are of great importance in chronic inflammation and in cancer. Published data have shown that CD44 has the ability to recruit leucocytes to vascular endothelium at sites of inflammation, which is one of the first steps in the inflammatory response. In cancer, deregulation of the adhesion mechanisms increases the ability of tumor cells to metastasise. This behavior seems to be explained by the existing relationship between hyaluronan, a basic component of the extracellular matrix and CD44, which is its major cell surface receptor. There are CD44 variant isoforms which are expressed on different types of normal cells. In addition some isoforms are overexpressed on tumor cells including breast, cervical, endometrial and ovarian cancer. This properly seems to be correlated with the metastatic potential of these cells. This review summarizes the available data on the possible prognostic role of the polymorphic CD44 protein family and its role as a tumor marker in gynaecological cancer.
引用
收藏
页码:633 / 640
页数:8
相关论文
共 50 条
  • [1] The CD44 protein family
    Ponta, H
    Wainwright, D
    Herrlich, P
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1998, 30 (03): : 299 - 305
  • [2] CD44 in cancer
    Naor, D
    Nedvetzki, S
    Golan, I
    Melnik, L
    Faitelson, Y
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2002, 39 (06) : 527 - 579
  • [3] Proteomic analysis of CD44(+) and CD44(-) gastric cancer cells
    Yu, Dayeon
    Shin, Hyun-Soo
    Choi, Go
    Lee, Yong Chan
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2014, 396 (1-2) : 213 - 220
  • [4] Proteomic analysis of CD44(+) and CD44(−) gastric cancer cells
    Dayeon Yu
    Hyun-Soo Shin
    Go Choi
    Yong Chan Lee
    [J]. Molecular and Cellular Biochemistry, 2014, 396 : 213 - 220
  • [5] CD44 AND CANCER SCREENING
    FOX, SB
    GATTER, KC
    JACKSON, DG
    SCREATON, GR
    BELL, MV
    BELL, JI
    HARRIS, AL
    SIMMONS, D
    FAWCETT, J
    [J]. LANCET, 1993, 342 (8870): : 548 - 549
  • [6] CD44 in Bladder Cancer
    Duex, Jason
    Theodorescu, Dan
    [J]. CANCERS, 2024, 16 (06)
  • [7] CD44 and cancer nanotherapy
    Wiwanitkit, Viroj
    [J]. JOURNAL OF MEDICAL HYPOTHESES AND IDEAS, 2012, 6 (01): : 3 - 3
  • [8] CD44 AND CANCER - REPLY
    TARIN, D
    MATSUMURA, Y
    [J]. LANCET, 1993, 341 (8839): : 252 - 253
  • [9] Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region
    Verkaik, NS
    van Steenbrugge, GJ
    van Weerden, WM
    Bussemakers, MJ
    van der Kwast, TH
    [J]. LABORATORY INVESTIGATION, 2000, 80 (08) : 1291 - 1298
  • [10] Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer
    Kawano, T
    Yanoma, S
    Nakamura, Y
    Ozeki, A
    Kokatsu, T
    Kubota, A
    Furukawa, M
    Tsukuda, M
    [J]. ACTA OTO-LARYNGOLOGICA, 2005, 125 (04) : 392 - 397